Monthly intravenous maintenance treatment with ustekinumab regains clinical response in patients with Crohn's disease who no longer respond to the drug when administered subcutaneously

Background: Several studies have assessed the efficacy of re-induction and subcutaneous intensification of ustekinumab (UST) to regain clinical remission of inflammatory bowel disease (IBD). However, very few have evaluated the effectiveness of intravenous UST for this purpose.Objectives: The aims o...

Descripción completa

Detalles Bibliográficos
Autores: López-Sáez, B, Altadill, A, Brunet-Mas, E, Garcia-Sagué, B, Melcarne, L, Llovet, LP, Frisancho, LE, Puy, A, Lario, S, Ramirez-Lazaro, MJ, del Estal, J, Villoria, A, Calvo, XC
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p6553
Acceso en línea:https://i3pt.portalinvestigacion.com/publicaciones/6553
Access Level:acceso abierto
Palabra clave:Crohn's disease
inflammatory bowel disease
ustekinumab
id ES_f1931263368f2b15391d459ea5c1918d
oai_identifier_str oai:i3pt.fundanetsuite.com:p6553
network_acronym_str ES
network_name_str España
repository_id_str
spelling Monthly intravenous maintenance treatment with ustekinumab regains clinical response in patients with Crohn's disease who no longer respond to the drug when administered subcutaneouslyLópez-Sáez, BAltadill, ABrunet-Mas, EGarcia-Sagué, BMelcarne, LLlovet, LPFrisancho, LEPuy, ALario, SRamirez-Lazaro, MJdel Estal, JVilloria, ACalvo, XCCrohn's diseaseinflammatory bowel diseaseustekinumabBackground: Several studies have assessed the efficacy of re-induction and subcutaneous intensification of ustekinumab (UST) to regain clinical remission of inflammatory bowel disease (IBD). However, very few have evaluated the effectiveness of intravenous UST for this purpose.Objectives: The aims of the study were to evaluate the efficacy of high-dose intravenous UST (USTiv) for regaining remission in Crohn's Disease (CD) and to assess the safety of the drug.Design: Observational, retrospective, single-center study.Methods: All patients who had received intravenous UST to regain remission until June 2023 were included. Clinical response was evaluated using the Harvey-Bradshaw Index. Drug survival was calculated using Kaplan-Meier curves.Results: Twenty-three patients (52% female, mean age 40.5 +/- 13.9) with CD were included. Seven (30%) patients had an incomplete primary response to UST, while 16 (70%) presented a secondary loss of response. Clinical response rates for USTiv administered monthly were 17/23 (73.9%) at week 8, 14/23 (60.9%) at week 16, and 10/12 (83.3%) at 1 year. Clinical remission rates were 11/23 (47.8%), 9/23 (39.1%), and 8/12 (66.7%), respectively. Median drug survival was 15.3 +/- 7.7 months. Two patients (8%) experienced recurrent mild respiratory infections. No patients discontinued USTiv due to adverse events.Conclusion: More than half of the patients with CD who underwent maintenance treatment with USTiv regained clinical response after failing with subcutaneous UST treatment. No significant adverse events were observed.SAGE PUBLICATIONS LTD2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/6553Therapeutic Advances in GastroenterologyISSN: 1756283XISSNe: 17562848reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:i3pt.fundanetsuite.com:p65532026-06-21T15:30:37Z
dc.title.none.fl_str_mv Monthly intravenous maintenance treatment with ustekinumab regains clinical response in patients with Crohn's disease who no longer respond to the drug when administered subcutaneously
title Monthly intravenous maintenance treatment with ustekinumab regains clinical response in patients with Crohn's disease who no longer respond to the drug when administered subcutaneously
spellingShingle Monthly intravenous maintenance treatment with ustekinumab regains clinical response in patients with Crohn's disease who no longer respond to the drug when administered subcutaneously
López-Sáez, B
Crohn's disease
inflammatory bowel disease
ustekinumab
title_short Monthly intravenous maintenance treatment with ustekinumab regains clinical response in patients with Crohn's disease who no longer respond to the drug when administered subcutaneously
title_full Monthly intravenous maintenance treatment with ustekinumab regains clinical response in patients with Crohn's disease who no longer respond to the drug when administered subcutaneously
title_fullStr Monthly intravenous maintenance treatment with ustekinumab regains clinical response in patients with Crohn's disease who no longer respond to the drug when administered subcutaneously
title_full_unstemmed Monthly intravenous maintenance treatment with ustekinumab regains clinical response in patients with Crohn's disease who no longer respond to the drug when administered subcutaneously
title_sort Monthly intravenous maintenance treatment with ustekinumab regains clinical response in patients with Crohn's disease who no longer respond to the drug when administered subcutaneously
dc.creator.none.fl_str_mv López-Sáez, B
Altadill, A
Brunet-Mas, E
Garcia-Sagué, B
Melcarne, L
Llovet, LP
Frisancho, LE
Puy, A
Lario, S
Ramirez-Lazaro, MJ
del Estal, J
Villoria, A
Calvo, XC
author López-Sáez, B
author_facet López-Sáez, B
Altadill, A
Brunet-Mas, E
Garcia-Sagué, B
Melcarne, L
Llovet, LP
Frisancho, LE
Puy, A
Lario, S
Ramirez-Lazaro, MJ
del Estal, J
Villoria, A
Calvo, XC
author_role author
author2 Altadill, A
Brunet-Mas, E
Garcia-Sagué, B
Melcarne, L
Llovet, LP
Frisancho, LE
Puy, A
Lario, S
Ramirez-Lazaro, MJ
del Estal, J
Villoria, A
Calvo, XC
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Crohn's disease
inflammatory bowel disease
ustekinumab
topic Crohn's disease
inflammatory bowel disease
ustekinumab
description Background: Several studies have assessed the efficacy of re-induction and subcutaneous intensification of ustekinumab (UST) to regain clinical remission of inflammatory bowel disease (IBD). However, very few have evaluated the effectiveness of intravenous UST for this purpose.Objectives: The aims of the study were to evaluate the efficacy of high-dose intravenous UST (USTiv) for regaining remission in Crohn's Disease (CD) and to assess the safety of the drug.Design: Observational, retrospective, single-center study.Methods: All patients who had received intravenous UST to regain remission until June 2023 were included. Clinical response was evaluated using the Harvey-Bradshaw Index. Drug survival was calculated using Kaplan-Meier curves.Results: Twenty-three patients (52% female, mean age 40.5 +/- 13.9) with CD were included. Seven (30%) patients had an incomplete primary response to UST, while 16 (70%) presented a secondary loss of response. Clinical response rates for USTiv administered monthly were 17/23 (73.9%) at week 8, 14/23 (60.9%) at week 16, and 10/12 (83.3%) at 1 year. Clinical remission rates were 11/23 (47.8%), 9/23 (39.1%), and 8/12 (66.7%), respectively. Median drug survival was 15.3 +/- 7.7 months. Two patients (8%) experienced recurrent mild respiratory infections. No patients discontinued USTiv due to adverse events.Conclusion: More than half of the patients with CD who underwent maintenance treatment with USTiv regained clinical response after failing with subcutaneous UST treatment. No significant adverse events were observed.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://i3pt.portalinvestigacion.com/publicaciones/6553
url https://i3pt.portalinvestigacion.com/publicaciones/6553
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SAGE PUBLICATIONS LTD
publisher.none.fl_str_mv SAGE PUBLICATIONS LTD
dc.source.none.fl_str_mv Therapeutic Advances in Gastroenterology
ISSN: 1756283X
ISSNe: 17562848
reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424168558133248
score 15,811543

Similares en LA Referencia